Compare Synchrony Financial (SYF) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synchrony Financial vs Tango Therapeutics Inc. — how do they compare? Synchrony Financial trades at $71.41 (market cap $23.94B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Synchrony Financial is far larger — about 6.4× Tango Therapeutics Inc.'s market cap, and Synchrony Financial pays a 1.85% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Synchrony Financial for 30 Days and Tango Therapeutics Inc. for 0 Days on average.
| SYF | TNGX | |
|---|---|---|
Market Cap | $23.94B | $3.75B |
Volume | 2,618,932 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $88.47 | $32.90 |
52-Week Low | $63.78 | $7.50 |
Typical Hold Time | 30 Days | 0 Days |
Enterprise Value | $24.18B | $2.77B |
Dividend Yield | 1.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synchrony Financial (SYF) trades at $73.59, down slightly by 0.04% on the day. The stock exhibits a bullish technical signal overall, with support near $73 and resistance at $75. Fundamentally, the company shows strong profitability with a 23.4% net income margin and a compelling valuation at a P/E of 7.55. Recent earnings have consistently beaten expectations, and strategic partnerships, like the one with OpenAI announced on August 17, 2026, highlight growth initiatives.
The outlook for SYF is positive, supported by robust analyst sentiment with a consensus price target of $87.50, implying significant upside. Key opportunities include high ROE and strategic expansions in digital finance. Risks involve potential consumer credit deterioration, as noted in broader market news on August 26, 2026, and increased investing cash outflows in 2026, which could pressure near-term liquidity.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
